Day: April 3, 2018

cCARE’s Dr. James Sinclair recently penned an editorial in the Times of San Diego outlining the ways in which the federal 340B drug pricing program favors large corporately-owned hospitals, while edging out independent, community-owned practices. While the program’s intent was to cut costs for cancer patients, the savings are not being passed onto patients, says Dr. Sinclair. And peer-reviewed research backs this claim.